Date: 2015-11-05
Type of information: IPO
Company: Oasmia Pharmaceutical (Sweden)
Investors:
Amount: $10.4 million
Funding type: IPO
Planned used: Proceeds from this offering will be used to fund: (i) new clinical trials and other regulatory requirements of Oasmia’s product and product candidates, (ii) production development, including validation batches, and (iii) other general corporate purposes, including employees, rent, and costs and expenses of being a U.S. public company.
Others: * On November 5, 2015, Oasmia Pharmaceutical announced the closing of an additional and partial exercise of the over-allotment option granted to the underwriters. The underwriters purchased 222,300 additional ADSs at a public offering price of $4.06 per ADS, representing 666,900 ordinary shares. This partial exercise of the over-allotment option brought the aggregate gross proceeds from the offering to approximately $10.4 million, before deducting underwriting discounts and commissions and other related expenses. Oasmia previously announced the closing of a U.S. underwritten public offering of American Depositary Shares, or ADSs, and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia’s ordinary shares. The Company granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and/or (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments. The underwriters exercised an option to purchase 111,150 such additional warrants, which transaction closed on October 28, 2015. * On October 29, 2015, Oasmia Pharmaceutical announced the closing of a U.S. underwritten public offering of American Depositary Shares (ADS), and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia’s ordinary shares. The Company received gross proceeds of approximately $9,500,354 from the initial securities sold in this offering, before deducting underwriting discounts, commissions and other related expenses. * On October 23, 2015, Oasmia Pharmaceutical announced the pricing of a U.S. underwritten public offering of ADS and one warrant to purchase such ADSs for each two ADSs sold in the offering, at an offering price of $4.06 per ADS and $0.0025 per warrant. Each ADS represents three of Oasmia’s ordinary shares. The Company expects to receive gross proceeds of approximately $9,500,076 million from this offering, before deducting underwriting discounts, commissions and other related expenses.The Company has also granted the underwriters a 45-day option to purchase up to (i) 350,880 additional ADSs and (ii) additional warrants to purchase up to 175,440 ADSs to cover over-allotments, if any. * On October 20, 2015, Oasmia Pharmaceutical has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission that, due to marketing conditions, will reduce the total amount of the size of its proposed public offering of American Depositary Shares and contemporaneous listing of the American Depositary Shares on the US Nasdaq Capital Market to $13 million and warrants corresponding to an additional maximum of $8.1 million. Oasmia will issue to each investor in its proposed offering of American Depositary Shares, or ADSs, one warrant to purchase such ADSs for each two ADSs sold in the offering. Joseph Gunnar & Co., LLC, and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. will act as joint book-running manager(s) for the proposed offering. * On September 28, 2015, Oasmia Pharmaceutical has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission to include the addition of a warrant to purchase additional ADSs representing its Ordinary Shares in connection with its proposed public offering on the US Nasdaq Capital Market. Oasmia will issue to each investor in its proposed offering of American Depositary Shares, or ADSs, one warrant to purchase such ADSs for each two ADSs sold in the offering. * On August 17, 2015, Oasmia Pharmaceutical has filed an updated registration statement on Form F-1/A with the Securities and Exchange Commission to include final full-year financials in connection with its proposed public offering of ADSs representing its Ordinary Shares and contemporaneous listing of the American Depositary Shares on the US Nasdaq Capital Market. * On August 3, 2015, Oasmia Pharmaceutical announced that it is extending its proposed initial public offering in order to add important material content to its Registration Statement that it believes strengthens the Company’s position among industry leading pharmaceutical oncology companies. * On July 7, 2015, Oasmia Pharmaceutical announced that the company has filed a registration statement on Form F-1/A for its proposed public offering and an application with NASDAQ for a US Listing. Ladenburg Thalmann is acting as lead book-running manager for the proposed offering, which is expected to close on July 30, 2015 at the latest, subject to customary closing conditions.
Therapeutic area: Cancer - Oncology - Veterinary medicine
